Trevi Therapeutics Inc (NASDAQ:TRVI) shares, rose in value on Thursday, May 08, with the stock price down by -0.90% to the previous day’s close as strong demand from buyers drove the stock to $6.60.
Actively observing the price movement in the last trading, the stock closed the session at $6.66. Referring to stock’s 52-week performance, its high was $7.39, and the low was $2.30. On the whole, TRVI has fluctuated by 24.53% over the past month.
With the market capitalization of Trevi Therapeutics Inc currently standing at about $659.30 million, investors are eagerly awaiting this quarter’s results, scheduled for in June.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that TRVI’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of TRVI currently trading nearly 4.12% and 9.27% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 56.08, while the 7-day volatility ratio is showing 5.79% which for the 30-day chart, stands at 6.81%. Furthermore, Trevi Therapeutics Inc (TRVI)’s beta value is 0.66, and its average true range (ATR) is 0.43.
A comparison of Trevi Therapeutics Inc (TRVI) with its peers suggests the former has fared considerably weaker in the market. TRVI showed an intraday change of -0.90% in last session, and over the past year, it grew by 124.49%%.
Data on historical trading for Trevi Therapeutics Inc (NASDAQ:TRVI) indicates that the trading volumes over the past 3 months, they’ve averaged 2.35 million. According to company’s latest data on outstanding shares, there are 93.60 million shares outstanding.
Nearly 40.90% of Trevi Therapeutics Inc’s shares belong to company insiders and institutional investors own 45.67% of the company’s shares. The stock has risen by 60.19% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the TRVI stock heading into the next quarter.
